ATRX and sarcoma: We further showed that, in both human and mouse sarcoma models, Atrx loss-of-function mutation led to a deficiency in CGAS/STING signaling that could be therapeutically targeted by a mouse-specific variant of the FDA-approved oncolytic herpesvirus TVEC.